Tomas Berl
Division of Renal Diseases and Hypertension
University of Colorado at Denver Health Sciences Center
Denver
Colorado 80262
USA
Name/email consistency: high
- Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. Berl, T. J. Renin. Angiotensin. Aldosterone. Syst (2009)
- Impact of solute intake on urine flow and water excretion. Berl, T. J. Am. Soc. Nephrol. (2008)
- Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers. Berl, T. Nephrol. Dial. Transplant. (2008)
- American Society of Nephrology Presidential Address 2005. Berl, T. J. Am. Soc. Nephrol. (2006)
- Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Berl, T., Henrich, W. Clinical J. American Society Nephrology : Cjasn (2006)
- Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. Berl, T., Hunsicker, L.G., Lewis, J.B., Pfeffer, M.A., Porush, J.G., Rouleau, J.L., Drury, P.L., Esmatjes, E., Hricik, D., Pohl, M., Raz, I., Vanhille, P., Wiegmann, T.B., Wolfe, B.M., Locatelli, F., Goldhaber, S.Z., Lewis, E.J. J. Am. Soc. Nephrol. (2005)
- Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. Berl, T. J. Am. Soc. Nephrol. (2004)
- Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent. Berl, T., Schwertschlag, U. Oncology (Williston Park, N.Y.) (2000)
